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Abstract  
BCR-ABL1 negative chronic myeloproliferative neoplasms (CMPNs) are a 
heterogeneous group of clonal haematological malignancies. Over the last years, some 
genetic events in tyrosine kinase (TK) genes have been described as causal events of 
these diseases. In order to find new genetic aberrations underlying these diseases, we 
have used dHPLC and FISH to analyse 17 genes from two families of receptor-TKs 
(families III and IV) and three families of cytoplasmatic-TKs (Syk, Abl and Jak) on 
samples from 44 BCR-ABL1 negative and JAK2V617F negative CMPN patients with 
different clinical phenotypes. While screening by FISH did not reveal novel 
chromosomal aberrations, we detected several sequence changes. Although none of 
them were frequent events, we identified a new potential activating mutation in the 
FERM domain of JAK2 (R340Q). None of the germline SNPs detected showed a 
different distribution between patients and controls. In summary, data presented here 
show that these genes are not frequently mutated or rearranged in CMPNs, suggesting 
that molecular events causing these disorders must be located in other genes. 
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Introduction  
BCR-ABL1 negative chronic myeloproliferative neoplasms (CMPNs) are a 
heterogeneous group of clonal haematological malignancies characterised by 
abnormal proliferation and survival of one or more myeloid lineage cells. In some 
cases, they can evolve to acute myeloid leukemia (AML). These diseases include 
both “classic” CMPNs (essential thrombocythemia –ET-, polycythaemia vera –PV- 
and idiopathic myelofibrosis –IMF-), and “atypical” or “non-classic” CMPNs (like 
chronic eosinophilic leukaemia, chronic neutrophilic leukemia, hypereosinophilic 
syndrome, mast cell disease and myeloid neoplasms with eosinophilia) [1]. Unlike 
chronic myeloid leukemia (CML), in which BCR-ABL1 fusion seems to be the 
primary cause of the disease, the pathogenesis of these CMPNs has remained elusive 
until recently. Over the last years, some genetic alterations (like mutations in JAK2) 
have been described, most of them activating tyrosine kinase (TK) genes that play a 
role similar to ABL1 in CML. 
TKs have an important role in cell growth and oncogenesis regulating multiple 
cellular processes. Gain-of-function abnormalities of TK genes can result in 
constitutive activation of the signalling pathways in which they are involved, 
contributing to tumour development and progression, and causing the abnormal 
proliferation and survival that characterize these diseases [2].  
The RTKs (receptor tyrosine kinase) class III genes include PDGFRA (4q12), 
PDGFRB (5q33), CSF1R (5q33), KIT (4q12) and FLT3 (13q12). RTKs class IV or 
FGFRs genes include FGFR1 (8p11), FGFR2 (10q26), FGFR3 (4p16) and FGFR4 
(5q35). All of them code for receptors characterised by several immunoglobulin (Ig)-
like domains in the extracellular ligand-binding region, a transmembrane domain, a 
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juxtamembrane domain and a splitted cytoplasmatic TK domain. Ligand binding to 
RTKs promotes receptor dimerization and subsequent activation of downstream 
signalling pathways. 
Whereas RTKs are able to initiate signal transduction pathways, CTKs are mediators 
in the same or in other pathways triggered by receptors with and without TK activity. 
Genes from Syk family, SYK (9p22) and ZAP70 (2q12), are both expressed in 
different cells from haematological tissue (mainly B and T cells). Both share the 
same structure, with two N-terminal SH2 protein-binding domains and a C-terminal 
TK domain. Genes from the Abl family (ABL1 located in 9q34 and ABL2 in 1q25) 
share an N-terminal SH3 domain, followed by a protein-binding SH2 domain, a 
central TK domain and a C-terminal DNA-binding domain. The Jak family is 
composed by four genes (JAK1 in 1p31, JAK2 in 9p24, JAK3 in 19p13 and TYK2 
in19p13). All of them are important players of JAK-STAT signalling pathway 
triggered by several different cytokines which has been found aberrantly activated in 
CMPNs [3] mostly as consequence of JAK2 mutations. Four JAKs share structural 
properties, with an N-terminal receptor-binding FERM domain, followed for an 
internal protein-binding SH2 domain, a unique autoinhibitory pseudokinase domain 
and a C-terminal TK domain.  
To date, some fusions different to BCR-ABL1 but involving also ABL1 (ETV6-ABL1) 
and other TKs (SYK, JAK2, FGFR1, PDGFRA, PDGFRB and FLT3) have been 
described in isolated CMPN cases. Some of these genes are rearranged with multiple 
partners (for a review see [4]) and others, like KIT and FLT3, have been found also 
mutated in several neoplasms. However, so far only the JAK2 V617F point mutation 
has been found recurrently in classic CMPNs and in a small number of non-classic 
CMPNs [5], so there is still a significant proportion of patients in which the disease-
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causing molecular event remains to be discovered. In addition, recent reports have 
addressed the role of germline variation in MPN pathogenesis, defining putative 
disease susceptibility loci [6-9] that would explain, at least in part, the familial 
clustering observed in these diseases [10,11]. 
The activating abnormalities described in neoplasms and the impact of the targeted 
therapy have pointed to TK coding genes as obvious candidates for systematic 
screenings in cancer. In fact, this is the focus of a comprehensive study worldwide 
using different approaches on different tumours [12-17].  
In this study, we have analysed all genes from the families III and IV of RTKs and 
Syk, Abl and Jak families of CTKs in a candidate-gene approach under the 
assumption that one or some of them could be altered in BCR-ABL1 negative and 
JAK2V617F negative CMPNs. All of these genes have a functional role in 
haematopoietic cells and at least one gene of each family has been found fused or 
mutated in a hematological neoplasm. Two approaches have been used for this 
screening: FISH (fluorescence in situ hybridization) to detect putative cryptic 
rearrangements, and a sensitive, high-throughput and low-cost screening method 
(dHPLC, denaturing HPLC) to detect sequence variants. 
Materials and methods 
Material from 44 different caucasian CMPN patients (28 males and 16 females) with 
normal karyotype from several hospitals from the north of Spain was obtained with 
informed consent from individual patients and the study was approved by the internal 
Ethics Commitee. Four patients were diagnosed of PV, 15 ET, four IMF and 21 
atypical CMPNs (aCMPN). Previously to the inclusion in our series, the BCR-ABL1 
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fusion was ruled out by conventional RT-PCR and FISH, and JAK2V617F mutation 
was negative by ARMS-PCR [18]. 
Cell suspensions in sufficient quantity and quality for FISH analysis were only 
available for 27 of the 44 patients for all the tests performed.  
In addition, the analysis by dHPLC included 20 normal (no disease) samples used as 
controls in order to check the frequency of sequence changes observed (putative 
polymorphisms) in our population. 
FISH 
FISH analysis was performed with commercial probes for PDGFRB and CSF1R 
(PDGFRB 5q33 Break Probe from Kreatech Biotechnology BV, Amsterdam, The 
Netherlands), ABL1 (Vysis® LSI® BCR/ABL ES Dual Color Translocation Probe, 
Vysis, Abbot Molecular, IL) and ABL2 (Vysis® LSI® 1p36/LSI® 1q25 and LSI® 
19q13/19p13 Dual Color Probe, Vysis, Abbot Molecular, IL). For the other genes, 
we designed two-colour FISH analyses with flanking probes (assay A) and one-
colour analyses with a gene-spanning probe (assay B) using BAC clones according to 
the position showed by UCSC Genome Browser (http://genome.ucsc.edu). These 
clones were obtained from BACPAC Resources Center at Children´s Hospital 
Oakland Research Institute (Oakland, CA) and Clone Resources at The Welcome 
Trust Sanger Institute (Hixton, UK) (additional file 1). Assay B was only performed 
in cases in which assay A showed an ambiguous pattern. 
Some of the TK genes selected for the analyses have been found fused with ETV6 
(12p13), so we also analyzed this gene with Vysis® LSI® ETV6 Dual Color 
Breakapart Probe (Abbott Molecular, Abbott Park, IL) in order to check if 
abnormalities in ETV6 could unravel new TK fusions. 
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BACs were extracted from liquid LB cultures with PhasePrep™ BAC DNA kit 
(Sigma-Aldrich, St Louis, MO) and labelled by nick translation using the CGH Nick 
Translation kit (Abbott Molecular, Abbott Park, IL). Coprecipitation, hybridization 
and washing were performed using standard methods. Results were analyzed with a 
fluorescence microscope (Nikon Eclipse 80i, Nikon Instruments Inc, Japan) and Isis 
FISH Imaging System (MetaSystems, Germany) software. Every probe was 
previously tested on normal metaphases and nuclei to establish a cut-off normal value 
for each assay. Two hundred interphase nuclei, and metaphases when available, were 
analyzed for each assay and patient.  
dHPLC analysis 
Genomic DNA was obtained from all the samples and whole-genome amplification 
(WGA) was performed (illustra™ GenomiPhi™ V2, GE Healthcare, Piscataway, NJ) 
in order to obtain enough material for the mutational analyses. Several tests using 
DNA from original and WGA samples were performed to check if both results 
matched, and no discrepancies were observed. 
For every gene screened, we selected exons coding the main functional protein 
domains such as the transmembrane (regulator) domain and the intracellular kinase 
domain. Due to its importance, the 25 coding exons of JAK2 were analysed in 23 
fragments. Primers located in flanking introns were designed using Primer3 [19] (for 
a list for primers, size of fragments and dHPLC conditions see additional files 2). For 
each fragment, a mutant control fragment was obtained from normal DNA changing a 
nucleotide in the forward or reverse primer depending on the melting profile. This 
“mutant” fragment allowed us to validate the dHPLC assay. Melting profiles of PCR 
fragments were calculated in each case by Navigator™ Software v1.6.2 
(Transgenomic Ltd., Omaha, NE), which helps to establish theoretical solvent 
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gradient and temperature/s of the analysis. Some fragments, due to their melting 
profiles, required more than one condition (temperature) to improve mutation 
detection. Conditions were then validated experimentally with appropriate controls. 
All the analyses were performed on a WAVE® 4500HT System (Transgenomic Ltd, 
Omaha, NE) with a DNASep® HT cartridge. 
All the PCR reactions were performed with AmpliTaq™ Gold (Applied Biosystems, 
Foster City, CA) under standard conditions. After PCR cycling, samples were 
subjected to several cycles of heating and cooling in order to create heteroduplex 
molecules which improve mutation detection by dHPLC. For each fragment, we 
sequenced two samples of each different elution profile and results were analysed 
with Mutation Surveyor v3.10 (SoftGenetics LLC, State College, PA). The genomic 
reference sequences were obtained from EnsEMBL. 
Association analysis 
Although our main goal was not to genotype SNPs, our mutational analysis revealed 
some germline SNPs in exons and flanking intronic regions. Since the genetic 
background has been proposed as an important predisposing factor for the 
development of these diseases [11], we carried out statistical analyses to determine 
putative associations between allele and genotype frequencies of the SNPs detected 
and the development of the disease. Although our patient and control series were 
small and a preliminary association must be verified in larger series, an unequal 
distribution of alleles and/or genotypes could unravel a putative linkage 
disequilibrium with real predisposing variants. 
For each sequence variant detected, we compared allele frequencies between patient 
and control groups using a two-tailed Fisher´s exact test. We used as control group 
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data obtained from 20 individuals without disease. In addition, when available, we 
also used genotype data from european individuals deposited in dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP/, caucasian populations). In addition, we 
compared genotype frequencies using a chi-square 2 x 3 contingency test with two 
degrees of freedom with two rows, one for patients and one for controls, and three 
columns, for the three different genotypes. As above, we compared patients vs our 
controls and patients vs controls plus european data from dbSNP when available. 
Hardy-Weinberg equilibrium test to ensure a correct genotyping were performed 
using SNPStats (http://bioinfo.iconcologia.net/index.php?module=Snpstats, [20]). 
mRNA splicing prediction analysis 
To check putative influence of intronic changes (both SNPs and mutations) on 
mRNA splicing, we used an mRNA splicing prediction web tool, Human Splicing 
Finder (http://www.umd.be/SSF/). This tool predicts the influence of nucleotide 
changes on mRNA splicing due to the effect on potential splice sites, splicing 
silencers and enhancers and branch points. 
Results  
FISH analysis 
For PDGFRA, we only observed an abnormal FISH result with assay A (gene-
flanking two colour labelled probes) in one aCMPN patient. This patient lost one red 
signal in 85% (170/200) of the nuclei and 8/10 metaphases analyzed, suggesting a 
deletion of the upstream 5´ part of PDGFRA. Subsequent analysis with a commercial 
FISH probe (Poseidon™ Repeat Free™ FIP-Chic-PDGFRA 4q12 Deletion/Break 
Dual-Color from Kreatech Biotechnology BV, Amsterdam, The Netherlands), 
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showed a pattern compatible with a FIP1L1-PDGFRA rearrangement not detected 
previously by conventional RT-PCR. 
All other samples showed normal hybridization patterns for all the TK genes included 
in the analyses. In addition, no abnormal pattern with commercial assay for ETV6 was 
found in any of the samples. 
Mutation and association analyses 
For each fragment, two samples from each different dHPLC elution profile were 
sequenced. We could detect 93 changes (see additional file 3) already described as 
polymorphisms in dbSNP. The most polymorphic gene was SYK with 11 SNPs 
detected, whereas the less polymorphic was ABL1 with only one SNP detected. Only 
seven of the 93 changes detected were non-synonymous (rs3822214 in KIT -M541L-, 
rs17881656 in FGFR3 -F384L-, rs351855 in FGFR4 -G388R-, rs2230723 in JAK2 –
L393V-, rs3213409 in JAK3 –V722I-, and rs12720356 –I684S- and rs55882956 –
R703W- both in TYK2). None of them showed different distribution either in patients 
vs controls or in patients vs controls plus dbSNP data (p>0.01). For rs55882956 in 
TYK2 no frequency data was available in dbSNP.  
Thirty-five of the 93 SNPs were detected in exons but without effect on translation. 
Again, none of them showed different distribution either in patients vs controls or in 
patients vs controls plus dbSNP data (p>0.01). Remarkably, two of them (rs246395 in 
PDGFRB and rs3733542 in KIT) showed differences (p=0.025 and p=0.005) in the 
allelic frequencies when dbSNP data were considered but no differences were 
observed considering only our control data, so maybe there are some differences 
between european populations for these SNPs. 
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The remaining 51 SNPs were detected in flanking intronic regions. Some of them 
could have a potential effect on splicing according to Human Splicing Finder 
prediction (additional file 3) but again none of them showed a different distribution in 
patients vs controls or in patients vs controls plus dbSNP data (p>0.01).  
Finally, we also found sequence changes not described in dbSNP (Table 1), all in a 
few number of individuals. Some of them were found both in patients and controls or 
only in control samples without effects on translation, except for 16283C>A (R925S) 
which was detected in JAK3 in 1/43 patients (2,3%) and in 1/20 controls (5%). Only 
57982G>A in CSF1R and 72438A>G in FLT3 were detected in a significant 
proportion of patients and controls: 2/44 (4,5%) and 3/44 (6,8%) respectively in 
patients and 2/20 (10%) and 3/20 (15%) respectively in controls. Interestingly, we 
found a non-synonymous sequence change in exon 8 of JAK2 (70507 G>A, R340Q) 
in a patient with an atypical CMPN (Figure 1A). The sequence pattern was 
compatible with a somatic event, although unfortunately we could not analyze another 
tissue of this patient to test this possibility. This change affects the FERM domain 
(Prosite #PS50057, InterPro #IPR000299). FERM domains are involved in protein-
protein interactions mainly in the localization of proteins to the plasma membrane and 
they are found in cytoskeletal-associated proteins. 
Discussion  
Over the last years, the knowledge about the pathogenesis of the BCR-ABL1 negative 
CMPNs has grown significantly, mainly due to the description of the JAK2V617F 
mutation in an important proportion of classic CMPNs, but also thanks to the 
characterization of multiple gene fusions involving several TK genes in a few number 
of CMPN patients. Taken together, all of these genetic lesions lead to TK activation, 
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resulting in aberrant signalling. Nevertheless, there are still a significant proportion of 
CMPN patients in which the molecular aberration which drives the disease remains 
unclear. In addition, during the past few years, some studies have shown association 
of different polymorphisms with the development of the neoplastic process, some of 
them in myeloproliferative neoplasms [6,14,21-24]. 
We considered the hypothesis that some TK genes, from families III and IV of RTKs 
and Syk, Jak and Abl families of CTKs, could be altered by cryptic genomic 
aberrations or point mutations in an important proportion of CMPN patients, 
explaining, at least in part, the development of these diseases. Some genes from these 
families have already been found mutated or rearranged in these and other tumours.  
Our FISH analyses did not show any new cryptic chromosomal rearrangement in the 
patients analyzed. This suggests that gene-fusions of these TK genes remain as very 
infrequent events in these disorders. A FIP1L1-PDGFRA fusion that had been missed 
by conventional RT-PCR was detected by FISH in one patient. Our results confirm 
that, as previously reported by other groups, FISH analysis is a good technique to 
detect the FIP1L1-PDGFRA gene fusion when conventional RT-PCR fails due to the 
variability of the breakpoints in FIP1L1. In fact, a multiplex PCR from genomic 
material has been recently reported to improve the detection of this rearrangement 
[25]. 
We chose denaturing-HPLC as a powerful method for somatic mutation discovery in 
neoplastic diseases. With serial dilutions of mutant controls, we have been able to 
detect a mutation present in 3-5% molecules of the sample (data not shown) whereas 
the sensitivity of direct sequencing is around 10-20%. 
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Applying a dHPLC comprehensive screening approach on candidate genes, we have 
detected, as expected, many sequence variants previously described as SNPs in 
dbSNP. Only seven of these changes were non-synonymous, 35 were synonymous 
and 51 were located in intronic regions close to exons. Some of them could have a 
potential effect on splicing according to in silico analyses using Human Splicing 
Finder. However, none of them showed differences in genotype and allelic 
frequencies between patients and controls, although two, rs246395 in PDGFRB and 
rs3733542 in KIT, showed differences between our population data and data 
deposited in dbSNP for european populations. This fact can be due to population 
substructure or differences in allelic frequencies between subpopulations. 
Recently, it has been reported that somatic mutations in JAK2 are preferentially found 
within a particular inherited haplotype that could explain almost half of the CMPN 
risk attributable to inherited factors. The risk haplotype is tagged by a SNP located 
close to V617F mutation [7-9]. Two hypotheses could explain this association [26]. 
First, (hypermutability hypothesis) the risk haplotype could tag a hypermutable locus. 
A second alternative explanation (“fertile ground” hypothesis) would be that although 
the somatic mutation rate is the same on different JAK2 haplotypes, only one of them 
would have a stronger selective advantage. Although the experimental design allowed 
us to detect sequence variants on intronic regions flanking exons, we could not 
directly test these hypotheses because our focus was on detection of sequence 
(somatic) variants in exons, so that we did not genotype the SNPs that have been 
found associated with the V617F mutation. In addition, the risk factor haplotype has 
been found in JAK2V617F positive cases, whereas our analyses were focused on 
JAK2V617F negative cases. In this regard, there is only one report showing a very 
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low association between JAK2 risk haplotype and the development of the disease in 
JAK2V617F negative cases, which was not confirmed in additional series [7]. 
We also found sequence changes not described previously as SNPs (table 1). Only 
one, 72438 A>G in FLT3 intron 16 with no potential effect on splicing, was observed 
in more than two patients and controls. Some of them were observed in one or two 
patients but also in control samples. Most of these sequence variants showed dHPLC 
and sequencing patterns compatible with changes present in the germ line, suggesting 
that they could be bona fide rare SNPs not yet described. However, no sample from 
another tissue was available to confirm this. Only 72454delTG and 84872C>A in 
FLT3 and 15525 T>C in JAK3 could have a putative effect on splicing according to 
in silico analyses performed with Human Splicing Finder. 
Finally, only two non-synonymous changes were observed, R340Q (70507 G>A) in 
JAK2 exon 8 and R925S (16286 C>A) in JAK3 exon 20. The latter was found in one 
out of 43 patients (a patient with ET) but also in an individual from the control group. 
This fact points to a rare SNP. However, this change affects the kinase domain and 
recently a non-synonymous SNP (rs3213409) in exon 15 (pseudokinase domain) of 
JAK3 (V722I) has been demonstrated as an activating point mutation in a patient with 
acute megakaryoblastic leukemia [27], although other genetic or environmental 
factors could promote the oncogenic effect of this variant. 
The R340Q sequence variant could be a driver mutation. In fact, sequence 
chromatogram shows a pattern compatible with a somatic mutation (wild type allele 
in a very low proportion and mutant allele in a proportion >50%, figure 1A) and this 
change affects to a JAK2 interspecies conserved aminoacid present also in JAK3 
(figure 1B). However, definite demonstration of its oncogenic potential should be 
made with functional analyses. This change affects the FERM domain, which is 
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involved in JAK2-receptor binding with a putative role on the regulation of the 
catalytic activity of the kinase [28]. Several different activating mutations apart from 
V617F have been described in the SH2 domain, the pseudokinase and the kinase 
coding regions of JAK2 (Figure 1A), but, to the best of our knowledge, mutations in 
the FERM domain of JAK2 have not been described to date. Recently, it has been 
reported that the function of V617F is dependent on the JAK2 FERM domain. This 
domain seems to be inhibitory in wild-type JAK2 to keep JAK2 in an inactive basal 
state [29]. In addition, some mutations with transforming activity have been 
described in the FERM domain in JAK1 and JAK3. For instance, JAK3P132T was 
described in an acute megakaryoblastic leukemia (AMKL) patient [27] and I87T was 
found in a patient with Down Syndrome and AMKL with a previous history of 
transient myeloproliferative disorder [30]. The JAK1K204M mutation has been 
recently described in an adult with a B acute lymphoblastic leukemia [28], also with 
transforming activity. Although JAK2R340Q could be a very rare mutation, it will be 
interesting to explore its recurrence. Unfortunately most studies on JAK2 are focused 
only in pseudokinase and kinase coding regions, so other changes such as this could 
be missed. 
In summary, both FISH and dHPLC mutation screening have shown that genes 
coding for RTKs class III and IV and the CTKs families Abl, Syk and Jak are not 
frequently mutated in BCR-ABL1 negative and V617FJAK2 negative CMPN patients. 
Moreover there are still some patients with PV in which the molecular event is not 
known. Our results also show that dHPLC is a reliable and efficient method for 
mutation detection, although most of the changes detected are SNPs or passenger 
variants that do not contribute to the neoplastic process [31]. Only the non-
synonymous mutation 70507 G>A (R340G) found in JAK2 exon 8, coding for FERM 
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domain, could be a novel oncogenic driver change, although this requires 
confirmation by functional analyses. 
Conclusions  
In conclusion, molecular events or cryptic rearrangements causing BCR-ABL1 
negative and V617F JAK2 negative CMPNs, if they exist, must be located in other 
TK coding genes or in genes coding for other molecules participating in the same 
signal transduction pathways. Despite the number of genes screened only a putative 
driver mutation, R340Q in JAK2, has been identified in a patient with atypical 
CMPN. Our results agree with other TK screening analyses performed mainly by 
resequencing in several cancers [12-17], in which the frequency of mutations in TK 
genes was found to be lower than initially expected. 
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Figures 
Figure 1. (A) Location of the R340Q mutation found in exon 8 of JAK2 affecting FERM 
domain. The position of activating mutations found to date is also indicated. (B) Clustal-W 
alignment (http://www.ebi.ac.uk/Tools/clustalw2) of human Jak proteins (left) and JAK2 
proteins in several species (right). Position 340 is conserved between human JAK2 and JAK3 
and highly conserved in different JAK2 proteins. 
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Tables 
Table 1  - Changes (not previously described as SNPs) observed in patients and controls. NA: not applicable.  
Frequency 
Gene Location Base1 Patient AA change Splicing effect2 
Patients Controls 
Patients 
PDGFRA Intron 20 59678 G>A 14752, 18148 NA No effect 2/44 (4,5%) 0/20 (0%) 2 aCMPN 
CSF1R Intron 19 57982 G>A 16737, 18708 NA No effect 2/44 (4,5%) 2/20 (10%) 2 ET 
KIT Intron 17 78549 T>C  NA No effect 0/44 (0%) 1/20 (5%)  
Intron 16 72438 A>G 15703, 15081, 11615 NA No effect 3/44 (6,8%) 3/20 (15%) 1 ET, 2 aCMPN 
Intron 16 72454delTG 9606 NA Breaks potential splicing site 2/44 (4,5%) 0/20 (0%) 1 IMF FLT3 
Intron 20 84872 C>A 16659 NA Breaks potential splicing site 1/44 (2,3%) 0/20 (0%) 1 ET 
FGFR3 Intron 12 11635insGCC 16547 NA No effect 1/44 (2,3%) 0/20 (0%) 1 ET 
Exon 10 6546 C>T 18708 NO (G435G) NA 1/44 (2,3%) 0/20 (0%) 1 ET 
FGFR4 
Exon 11 6846 C>T 14886 NO (A501A) NA 1/44 (2,3%) 0/20 (0%) 1 ET 
Intron 4 149290 C>T 17826  No effect 1/41 (2,5%) 0/20 (0%) 1 ET 
ABL1 
Intron 9 166395 C>T   No effect 0/44 (0%) 1/20 (5%)  
ZAP70 Intron 2 10431delC 16659  No effect 1/44 (2,3%) 0/20 (0%) 1 ET 
Intron 13 118975 C>T 15703  No effect 1/43 (2,3%) 0/20 (0%) 1 ET 
JAK1 
Exon 20 126901 C>T 16547 NO (D947D) NA 1/43 (2,3%) 0/20 (0%) 1 ET 
Exon 8 70507G>A 16572 R340Q NA 1/44 (2,3%) 0/20 (0%) 1 aCMPN 
Exon 19 96506 C>T 18148 NO (D820D) NA 1/44 (2,3%) 0/20 (0%) 1 aCMPN JAK2 
Exon 25 141607 C>T 18630 Non coding region NA 1/44 (2,3%) 0/20 (0%) 1 PV 
Exón 15 12791G>A 14837 NO (L643L) NA 1/43 (2,3%) 0/20 (0%) 1 ET 
Intron 19 15525 T>C   Breaks potential branch site 0/43 (0%) 1/20 (5%)  
Exon 20 16286 C>A 14837 R925S NA 1/43 (2,3%) 1/20 (5%) 1 ET 
JAK3 
Intron 20 16389 C>T   No effect 0/43 (0%) 2/20 (10%)  
Intron 12 16955 C>T 19537, 16547  No effect 2/43 (4,7%) 0/20 (0%) 1 PV, 1 ET 
Exón 18 24345 C>T  NO (R952R) NA 0/43 (0%) 1/20 (5%)  TYK2 
Exón 23 27725 C>T 21762 Non coding region NA 1/43 (2,3%) 0/20 (0%) 1 PV 
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1 numbering according EnsEMBL (http://www.ensembl.org) data: PDGFRA (ENSG00000134853), PDGFRB (ENSG00000113721), CSF1R (ENSG00000182578), KIT (ENSG00000157404), FLT3 
(ENSG00000122025), FGFR1 (ENSG00000077782), FGFR2 (ENSG00000066468), FGFR3 (ENSG00000068078), FGFR4 (ENSG00000160867), JAK1 (ENSG00000162434), JAK2 (ENSG00000096968), JAK3 
(ENSG00000105639), TYK2 (ENSG00000105397), ABL1 (ENSG00000097007), ABL2 (ENSG00000143322), SYK (ENSG00000165025), ZAP70 (ENSG00000115085). 
2
 data from Human Splicing Finder (http://www.umd.be/SSF/) 
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Additional files 
Additional file 1 – BAC clones selected for FISH assays type A (two-colour FISH 
with flanking probes) and type B (one-colour FISH with a gene-spanning probe). 
For the assay A, two clones on each side of the gene were selected and labelled in 
order to obtain a good and strong signal. For FGFR3 only one clone on each side was 
sufficient. These clones were labelled with Spectrum Orange dUTP* (SO, 5’ clone) 
and Spectrum green dUTP* (SG, 3’ clone) both from Abbott Molecular (Abbott Park, 
IL). The normal hybridization pattern for assay A would be two green-red fusion 
signals. Clones selected for assay B were labelled with Spectrum Orange dUTP* 
(SO). For this assay the normal hybridization pattern would be two separated red 
signals..  
Additional file 2 – Primers and dHPLC conditions used for mutation scan 
analysis. 
Three primers were used for each fragment. Patient samples were amplified with 
forward (Fw) and reverse (Rv) primer. A control DNA was amplified with a mutant 
primer (Fw + Rv mut or Fw mut + Rv) to generate mutant control DNA used to 
validate the assay. Changes in the sequence of the primers to generate mutant control 
fragment are showed underlined. In addition, the tables show the size of the PCR 
fragment analyzed and the temperature of the dHPLC assay. TM: transmembrane 
domain; TK: Tyrosine Kinase domain. 
Additional file 3 – SNPs detected by mutation scanning of candidate genes. 
